Start for free
Start for free
LI

LODH Immunology Fund

Europe, Geneve, Switzerland, Geneva

Description

The LODH Immunology Fund is a Swiss open-ended mutual fund managed by Lombard Odier Darier Hentsch & Cie, a Swiss private bank.

Investor Profile

LODH Immunology Fund has made 6 investments, with 0 in the past 12 months and 17% as lead.

Stage Focus

  • Series A (50%)
  • Series Unknown (33%)
  • Series B (17%)

Country Focus

  • Switzerland (67%)
  • Denmark (33%)

Industry Focus

  • Biotechnology
  • Medical
  • Health Care
  • Pharmaceutical
  • Therapeutics
  • Manufacturing
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does LODH Immunology Fund frequently co-invest with?

IF
Ingro Finanz AG
Europe, Basel-Landschaft, Switzerland, Bubendorf
Co-Investments: 1
InnoVentures Capital Partners
InnoVentures Capital Partners
North America, Utah, United States, Salt Lake City
Co-Investments: 1
Novartis Venture Fund
Novartis Venture Fund
Europe, Basel-Stadt, Switzerland, Basel
Co-Investments: 4
Apax Partners Development
Apax Partners Development
Europe, Ile-de-France, France, Paris
Co-Investments: 1
Aravis Ventures
Aravis Ventures
Europe, Zurich, Switzerland, Zürich
Co-Investments: 2
BB
BZ Bank
Europe, Solothurn, Switzerland, Wiler
Co-Investments: 2
BankInvest Biomedical Venture
Co-Investments: 1
Index Ventures
Index Ventures
North America, California, United States, San Francisco
Co-Investments: 2
Dansk Erhvervsinvestering
Co-Investments: 1
Pictet Private Equity Investors S.A.
Pictet Private Equity Investors S.A.
Europe, Geneve, Switzerland, Geneva
Co-Investments: 2

What are some of recent deals done by LODH Immunology Fund?

NovImmune

Plan-les-ouates, Geneve, Switzerland

NovImmmune develops therapeutic monoclonal antibodies to treat patients suffering from immune-related disorders.

BiotechnologyMedicalPharmaceutical
Series UnknownMay 12, 2009
Amount Raised: $54,800,000
NovImmune

Plan-les-ouates, Geneve, Switzerland

NovImmmune develops therapeutic monoclonal antibodies to treat patients suffering from immune-related disorders.

BiotechnologyMedicalPharmaceutical
Series BJun 1, 2006
Amount Raised: $46,000,000
ESBATech

Schlieren, Zurich, Switzerland

ESBATech develops fully human antibody fragments for therapeutic applications, applying the single-chain antibody framework.

BiotechnologyHealth CareTherapeutics
Series AMay 14, 2002
Amount Raised: $8,996,617
7TM Pharma

Lyngby, Hovedstaden, Denmark

7TM Pharma is a biotech company that discovers and develops drugs with a primary therapeutic focus on diabetes, asthma, and more.

BiotechnologyHealth CareTherapeutics
Series ASep 27, 2001
Amount Raised: $15,000,000
Genmab

Copenhagen, Hovedstaden, Denmark

Genmab is a biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer.

BiotechnologyHealth CareManufacturingMedical
Series UnknownJun 13, 2000
Amount Raised: $40,500,000
NovImmune

Plan-les-ouates, Geneve, Switzerland

NovImmmune develops therapeutic monoclonal antibodies to treat patients suffering from immune-related disorders.

BiotechnologyMedicalPharmaceutical
Series AMay 1, 2000
Amount Raised: $14,000,000
c-shape-1
c-shape-2

Ready to Raise Capital?

Founders in our network have raised from Y Combinator, Sequoia, a16z, and more. You could be next.

Find investors

Pages

Find investorsPricing

Free tools

Pre-Money and Post-Money Valuation Calculator